This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Tibotec Pharmaceuticals, Ireland
ClinicalTrials.gov Identifier:
NCT00665847
First received: April 22, 2008
Last updated: April 2, 2015
Last verified: April 2015
Results First Received: June 14, 2012  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: HIV-1
Interventions: Drug: Etravirine (TMC125)
Drug: Optimized background regimen (OBR)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
In total, 41 investigators in 13 countries enrolled patients in study TMC125-C213. A total of 103 patients were documented as being enrolled in the study, however 2 patients were randomized in error. Therefore, 101 patients were enrolled and treated with etravirine (ETR) also known as TMC125 and included in the intent-to-treat (ITT) population.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
TMC125 TMC125 dosed according to body weight (kg) from 100 mg to 200 mg twice a day

Participant Flow:   Overall Study
    TMC125
STARTED   101 
COMPLETED   76 
NOT COMPLETED   25 
Adverse Event                8 
Withdrawal by Subject                2 
Subject non-compliant                8 
Subject reached a virologic endpoint                4 
Resistance to TMC125                1 
Subject ineligible to continue the trial                1 
Switch to Commercial Medication                1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
TMC125 TMC125 dosed according to body weight (kg) from 100 mg to 200 mg twice a day

Baseline Measures
   TMC125 
Overall Participants Analyzed 
[Units: Participants]
 101 
Age 
[Units: Years]
Mean (Standard Deviation)
 12.2  (2.99) 
Gender 
[Units: Participants]
 
Female   64 
Male   37 
Age Customized 
[Units: Participants]
 
>=6 to <12 years   41 
>=12 to <18 years   60 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   The Number of Patients With Treatment-emergent Adverse Events (TEAEs)   [ Time Frame: 48 weeks ]

2.  Primary:   The Percentage of Patients With Treatment-emergent Adverse Events (TEAEs)   [ Time Frame: 48 weeks ]

3.  Secondary:   Population Pharmacokinetic (PK) Estimates of Etravirine/TMC125 (ETR): Area Under the Plasma Concentration-time Curve Over 12 Hours at Steady-state (AUC12h)   [ Time Frame: Weeks 4-48 ]

4.  Secondary:   Population Pharmacokinetic (PK) Estimates of Etravirine/TMC125 (ETR): Trough Plasma Concentration (C0h)   [ Time Frame: Week 48 ]

5.  Secondary:   Population Pharmacokinetic (PK) Estimates of Etravirine/TMC125 (ETR): Maximum Plasma Concentration (Cmax)   [ Time Frame: Week 4 ]

6.  Secondary:   Percentage of Patients With Virologic Response at Week 24   [ Time Frame: Week 24 ]

7.  Secondary:   Change From Baseline in Human Immunodeficiency Virus – Type 1 (HIV-1) Ribonucleic Acid (RNA) in Plasma Over Time   [ Time Frame: Baseline, Week 48 ]

8.  Secondary:   The Change From Baseline in CD4 Cell Counts Over Time   [ Time Frame: Baseline, Week 48 ]

9.  Secondary:   The Emergence of Non-nucleoside Reverse Transcriptase Inhibitor Resistance-associated Mutations (NNRTI RAMs) in Patients Classified as Virologic Failures   [ Time Frame: Baseline and Endpoint (up to Week 48) ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information